Ed Kaye, departing CEO of Stoke Therapeutics
Stoke CEO Ed Kaye to depart shortly after inking Biogen pact and before its first Phase 3 trial
In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the company, weeks before the Phase 3 trial of its lead drug is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
